Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07075705 · ClinicalTrials.gov registry record · NA

Transperineal Micro-ultrasound for the Detection of Prostate Cancer During Biopsy

A NA study, sponsored by Roswell Park Cancer Institute.

Not yet
Registry status
NA
Development phase
138
Enrollment target

NCT07075705: Clinical Trial NA study, sponsored by Roswell Park Cancer Institute.

NCT07075705 is a NA study that has not yet begun recruiting, run by Roswell Park Cancer Institute. The registered enrollment target is 138 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07075705, a NA study, has not yet begun recruiting, sponsored by Roswell Park Cancer Institute.

NOT YET RECRUITING
Registry status
NA
Development phase
138 participants
Enrollment target

Study Summary

This clinical trial studies whether transperineal micro-ultrasound can be used to detect prostate cancer during biopsy. Transrectal ultrasound is often used during prostate biopsy. Transrectal ultrasound imaging is a procedure in which a probe that sends out high-energy sound waves is inserted into the rectum. The sound waves are bounced off internal tissues or organs and make echoes. The echoes form a picture of body tissue called a sonogram. Transrectal ultrasound is used to look for abnormalities in the rectum and nearby structures, including the prostate. The images are used to guide the prostate biopsy. Transperineal micro-ultrasound is completed by placing a probe over the skin between the scrotum and anus (perineum). It is a high-resolution ultrasound at 29 megahertz (MHz) (compared to traditional ultrasound at 6-9 MHz). This higher frequency allows for an improved spatial resolution. This improved spatial resolution is approximately the diameter of a prostatic duct, and therefore, may be able to visualize slight changes in the structure of prostatic ducts that are not possible with standard transrectal ultrasound. Transperineal micro-ultrasound may be more effective in detecting prostate cancer during biopsy.

Primary Outcome

At the first stage, 28 patients will be enrolled. If the procedure was successful in at least 18 patients, the procedure will be considered feasible, and the study will proceed to the next stage. If less than 18 successes were observed, the study team will determine whether to continue the trial based on the data collected.

Interventions

  • PROCEDURE Magnetic Resonance Imaging
  • PROCEDURE Biopsy of Prostate
  • PROCEDURE Micro-ultrasound Imaging

Trial Details

FieldValue
Enrollment Target 138 participants
Start Date 2026-07-15
Est. Completion 2027-01-15
Phase NA
Roswell Park Cancer Institute

365 total trials

What is known before NCT07075705 opens enrollment

NCT07075705 is an interventional study that assigns participants to a tested intervention. The registered 138 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower).

The record links to 0 conditions, and to 3 interventions - of which Magnetic Resonance Imaging is the first listed.

NCT07075705 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT07075705 about?

NCT07075705 is a clinical study titled "Transperineal Micro-ultrasound for the Detection of Prostate Cancer During Biopsy". This clinical trial studies whether transperineal micro-ultrasound can be used to detect prostate cancer during biopsy. Transrectal ultrasound is often used during prostate biopsy. Transrectal ultrasound imaging is a procedure in which a probe that sends out high-energy sound waves is inserted into ...

What is the current status of trial NCT07075705?

This trial is currently not yet recruiting. It is a NA study. The enrollment target is 138 participants. The study started on 2026-07-15. Estimated completion is 2027-01-15.

What interventions are being tested in trial NCT07075705?

The interventions under investigation include: Magnetic Resonance Imaging (PROCEDURE), Biopsy of Prostate (PROCEDURE), Micro-ultrasound Imaging (PROCEDURE).

Who is sponsoring clinical trial NCT07075705?

This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT07075705's enrollment target sits among peer trials

138 720th of 2000 higher than 1,279 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04402788 · 138 participants · Phase 2

    Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial

  • NCT04883255 · 138 participants · Early Phase 1

    Cannabis Use, Cognition, and the Endocannabinoid System in HIV

  • NCT05620784 · 138 participants · Phase 3

    Intra-operative Loop Diuretics to Improve Same-day Discharge Rates After HoLEP

  • NCT05832086 · 138 participants · Phase 2

    Intermittent Fasting Using a Fasting-Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07075705, the US trial registry maintained by the National Library of Medicine. NCT07075705 (mid enrollment · none site footprint · not yet recruiting) retrieved and formatted by PlainTrial, see methodology.